Skip to main content
Figure 3 | BMC Cancer

Figure 3

From: Successful control of heavily pretreated metastatic gastric cancer with the mTOR inhibitor everolimus (RAD001) in a patient with PIK3CA mutation and pS6 overexpression

Figure 3

Immunohistochemical (IHC) staining for pS6 (serine 235/236 and serine 240/244) and PTEN was performed just before and during the everolimus re-treatment. All photographs were taken at 200 X magnification. Before everolimus re-treatment, the tumor cells exhibited strong positivity for pS6 in more than 50% of the tumor, whereas PTEN was weakly positive in tumor cells compared with the internal controls of endothelial cells (A). After 2 months of everolimus re-treatment, the tumor cells in the follow-up biopsy were completely negative for pS6. However, the intensity of PTEN was notably increased in all tumor cells (B).

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us